Vandria reported first‑in‑human Phase I data for VNA‑318, an orally available, brain‑penetrant mitophagy‑boosting candidate for Alzheimer’s disease, showing target engagement and tolerability consistent with daily dosing. The company plans a Series B to fund a Phase 2 program following these early human signals. Management highlighted pharmacokinetics and biomarker trends as the rationale for advancing VNA‑318 into a controlled efficacy study. Vandria said the funds will support expanded clinical development as it seeks partners or a larger financing to move into proof-of-concept testing.